GBG Forschungs GmbH (German Breast Group)

Industry / private company


Location: Neu-Isenburg, Germany (DE) DE

ISNI: 0000000404572954

ROR: https://ror.org/03c8hnh70

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients with Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial (2022) Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stotzer O, Fasching P, et al. Journal article DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status (2021) Jurmeister P, Weber K, Villegas S, Karn T, Untch M, Thieme A, Mueller V, et al. Journal article Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (BMC Cancer, (2021), 21, 1, (920), 10.1186/s12885-021-08656-0) (2021) Stuerken C, Moebus V, Milde-Langosch K, Schmatloch S, Fasching P, Rueschoff J, Stickeler E, et al. Journal article, Erratum AGO Algorithms for the Treatment of Breast Cancer: Update 2021 AGO-Algorithmen zur Behandlung von Brustkrebs: Update 2021 (2021) Schneeweiss A, Fasching P, Fehm T, Gerber B, Jackisch C, Loibl S, Schmidt M, et al. Journal article AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update (2021) Friedrich M, Kühn T, Janni W, Müller V, Banys-Pachulowski M, Kolberg-Liedtke C, Jackisch C, et al. Journal article, Review article TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (2021) Stuerken C, Moebus V, Milde-Langosch K, Schmatloch S, Fasching P, Rueschoff J, Stickeler E, et al. Journal article Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials (2021) Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, et al. Journal article Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2021) Marmé F, Solbach C, Michel L, Schneeweiss A, Blohmer JU, Huober J, Fasching P, et al. Journal article Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials (2021) Furlanetto J, Marmé F, Seiler S, Thode C, Untch M, Schmatloch S, Schneeweiss A, et al. Journal article Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference (2021) Untch M, Fasching P, Brucker SY, Budach W, Denkert C, Haidinger R, Huober J, et al. Journal article, Review article